8
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      A combinatorial approach to identify calpain cleavage sites in the Machado-Joseph disease protein ataxin-3.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Ataxin-3, the disease protein in Machado-Joseph disease, is known to be proteolytically modified by various enzymes including two major families of proteases, caspases and calpains. This processing results in the generation of toxic fragments of the polyglutamine-expanded protein. Although various approaches were undertaken to identify cleavage sites within ataxin-3 and to evaluate the impact of fragments on the molecular pathogenesis of Machado-Joseph disease, calpain-mediated cleavage of the disease protein and the localization of cleavage sites remained unclear. Here, we report on the first precise localization of calpain cleavage sites in ataxin-3 and on the characterization of the resulting breakdown products. After confirming the occurrence of calpain-derived fragmentation of ataxin-3 in patient-derived cell lines and post-mortem brain tissue, we combined in silico prediction tools, western blot analysis, mass spectrometry, and peptide overlay assays to identify calpain cleavage sites. We found that ataxin-3 is primarily cleaved at two sites, namely at amino acid positions D208 and S256 and mutating amino acids at both cleavage sites to tryptophan nearly abolished ataxin-3 fragmentation. Furthermore, analysis of calpain cleavage-derived fragments showed distinct aggregation propensities and toxicities of C-terminal polyglutamine-containing breakdown products. Our data elucidate the important role of ataxin-3 proteolysis in the pathogenesis of Machado-Joseph disease and further emphasize the relevance of targeting this disease pathway as a treatment strategy in neurodegenerative disorders.

          Related collections

          Author and article information

          Journal
          Brain
          Brain : a journal of neurology
          Oxford University Press (OUP)
          1460-2156
          0006-8950
          May 01 2017
          : 140
          : 5
          Affiliations
          [1 ] Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.
          [2 ] Centre for Rare Diseases, University of Tübingen, Tübingen, Germany.
          [3 ] Center for Ophthalmology, Institute for Ophthalmic Research, University of Tübingen, Tübingen, Germany.
          [4 ] German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.
          [5 ] Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Oslo, Norway.
          [6 ] Department of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research and Center of Neurology, University of Tübingen, Tübingen, Germany.
          [7 ] Paediatric Hematology and Oncology, University Children's Hospital Tübingen, Tübingen, Germany.
          [8 ] Werner Reichardt Centre for Integrative Neuroscience, University of Tübingen, Tübingen, Germany.
          [9 ] Department of (Neuro)Pathology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
          [10 ] Swammerdam Institute for Life Sciences, Center for Neuroscience, University of Amsterdam, Amsterdam, The Netherlands.
          Article
          3063601
          10.1093/brain/awx039
          28334907
          07737186-fcdc-48ed-a305-c5935050db92
          History

          ataxin-3,calpains,cleavage sites,spinocerebellar ataxia type 3,Machado-Joseph disease

          Comments

          Comment on this article